 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. PR...

HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.

HARMONY BIOSCIENCES PRESIDENT &amp; CEO JEFFREY M. DAYNO, M.D., NAMED TO 2023 PHARMAVOICE 100 LIST OF TOP INDUSTRY LEADERS HARMONY BIOSCIENCES PRESIDENT &amp; CEO JEFFREY M. DAYNO, M.D...

HARMONY BIOSCIENCES PRESIDENT & CEO JEFFREY M. DAYNO, M.D., NAMED TO 2023 PHARMAVOICE 100 LIST OF TOP INDUSTRY LEADERS

HRMY's total volume now sits at 1.7M. The +-1.34% price change was insignificant, leaving IBM's price at $37.52...

The volume for Harmony Biosciences Holdings stock increased for one day, resulting in a record-breaking daily growth of 237% of the 65-Day Volume Moving Average

HARMONY BIOSCIENCES TO PARTICIPATE IN 2023 CANTOR GLOBAL HEALTHCARE CONFERENCE HARMONY BIOSCIENCES TO PARTICIPATE IN 2023 CANTOR GLOBAL HEALTHCARE CONFERENCE PR Newswire PLYMOUTH MEETING, Pa., Sept...

HARMONY BIOSCIENCES TO PARTICIPATE IN 2023 CANTOR GLOBAL HEALTHCARE CONFERENCE

HARMONY BIOSCIENCES ANNOUNCES US FOOD &amp; DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT FOR TREATMENT OF IDIOPATHIC HYPERSOMNIA HARMONY BIOSCIENCES ANNOUNCES US FOOD &amp; DRUG...

HARMONY BIOSCIENCES ANNOUNCES US FOOD & DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT FOR TREATMENT OF IDIOPATHIC HYPERSOMNIA

Unraveling the Factors That Could Limit the Company's Future OutperformanceRelated Stocks: HRMY...

Harmony Biosciences Holdings Inc (HRMY): A Deep Dive into Its Performance Potential

California State Teachers Retirement System lessened its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY  Free Report) by 1.5% in the 1st quarter, according to its most...

California State Teachers Retirement System Reduces Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

US Bancorp DE boosted its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY  Free Report) by 25.0% during the 1st quarter, according to its most recent 13F filing with the...

US Bancorp DE Grows Stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Principal Financial Group Inc. reduced its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY  Free Report) by 3.0% in the 1st quarter, HoldingsChannel.com reports. The...

Principal Financial Group Inc. Sells 5,691 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

HARMONY BIOSCIENCES REITERATES CONFIDENCE IN WAKIX (PITOLISANT) PATENTS FOLLOWING FAVORABLE DECISION BY U.S. PATENT AND TRADEMARK OFFICE (USPTO) TO DENY PETITION FOR REEXAMINATION HARMONY BIOSCIENCES REITERATES CONFIDENCE IN WAKIX (PITOLISANT) PATENTS FOLLOWING FAVORABLE DECISION BY U.S. PATENT AND...

HARMONY BIOSCIENCES REITERATES CONFIDENCE IN WAKIX (PITOLISANT) PATENTS FOLLOWING FAVORABLE DECISION BY U.S. PATENT AND TRADEMARK OFFICE (USPTO) TO DENY PETITION FOR REEXAMINATION

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Watchers	387
52-Wk Low	$29.81
52-Wk High	$62.09

Market Cap	$2.03B
Volume (M)	521,141.00
52-Wk High	$62.09
52-Wk Low	$29.81

HRMY Harmony Biosciences Holdings Inc

About

Feed

News

Sentiment

Earnings

Fundamentals